Background: Abacavir is a potent, novel 2′-deoxyguanosine analogue reverse transcriptase inhibitor (NRTI) which effectively suppresses HIV-1 replication. To date, there is no pharmacokinetic study in patients with renal impairment. Methods: Five HIV-1-infected patients with various degrees of renal dysfunction (creatinine clearance 60, 40, 25, 20 and 1 haemodialyzed patient) were evaluated after being treated for at least 2 months with multi-antiretroviral therapy including abacavir. After an overnight fast, the subjects received their abacavir dosage (600 or 300 mg). Blood samples were withdrawn and plasma concentrations determined. A nonparametric pharmacokinetic analysis was then performed. The dialysability of abacavir was also evaluated. Results: Time of maximum plasma concentration (Tmax) was constant among the subjects with a mean value of 0.7 ± 0.27 h (range 0.33–1). Maximum plasma concentration (Cmax) ranged from 2.76 to 4.15 mg/l (mean 3.44 ± 0.59). The elimination half-life ranged from 1.31 to 2.67 h (mean 2.08 ± 0.51). Normalized Cmax/dose ranged from 0.007 to 0.014 mg/l and normalized AUC(0-inf)/dose ranged from 0.014 to 0.035 mg·h/l. In haemodialysis the dialysance was 60–80 ml/min with a fractional drug removal of 24% during a 4-hour haemodialysis session with a high permeability membrane. Discussion: In our patients, absorption, elimination and distribution phases were not altered by renal insufficiency. Furthermore, our pharmacokinetic data are similar to those obtained in patients with normal renal function. Therefore, dosage adjustment is not necessary in patients with renal insufficiency. In haemodialyzed patients, treatment can be administered independently to the dialysis session because of the negligible elimination of abacavir in the dialysate.

Keywords:
Abacavir, Pharmacokinetics, Renal insufficiency, Haemodialysis
1.
Kimmel PL, Phillips TO, Furreira-Centeno A et al: HIV-associated immune-mediated renal disease. Kidney Int 1993;44:1327–1340.
2.
Casanova S, Mazzucco G, di Belgiojoso B et al: Pattern of glomerular involvement in human immunodeficiency virus-infected patients: An Italian study. Am J Kidney Dis 1995;26:446–453.
3.
Daluge SM, Good SS, Faleto MB et al: 1592U89: A novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997;41:1082–1093.
4.
Foster RH, Faulds D: Abacavir. Drugs 1998;55:729–738.
5.
Tompson M, Torres G, Ensttom T et al: Single-dose plasma profiles of abacavir (ABC, 1592) in HIV-1-infected individuals with renal failure. 12th World AIDS Conference, Poster No. 42278.
6.
Aymard G, Legrand M, Trichereau N, Diquet B: Determination of twelve antiretroviral agents in human plasma sample using reverse-phase high-performance liquid chromatography. Chromatogr B Biomed Sci Appl 2000;744:227–240.
7.
Gotch FA: Hemodialysis: Technical and kinetic considerations; in Brenner BM, Rector FC (eds): The Kidney. Philadelphia, Saunders, 1976, pp 1672–1704.
8.
Lee CS, Marbury TC: Drug therapy in patients undergoing hemodialysis, clinical pharmacokinetic considerations. Clin Pharmacokinet 1984;9:42–46.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.